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same EGFR mutation, do not behave alike, and thus RNA
expression classifiers may help define different behaviors
within these genetic subsets.
The second problem is as important and perhaps more
subtle but just as pervasive. To answer a question, the
question must be clearly defined, and one must use well-
defined and appropriate datasets to find useful answers. The
goal of this study is to define a “prognostic” classifier (often
defined as outcome independent of therapy) and not a “pre-
dictive” one (defining which patients will benefit from ther-
apy). However, it is very important to define the projected use
of such a “prognostic” classifier. It is stated in the Introduc-
tion of the article that such risk classifiers are useful in
defining patients destined to relapse and thus might benefit
from adjuvant therapy. Adjuvant chemotherapy clearly im-
proves survival, and adjuvant radiation clearly alters the risk
of local relapse. Thus, ideally, clinically useful prognostic
classifications should assist in the definition of a subset of
patients who are at high risk for relapse without adjuvant
therapy, and within this subset, there are hopefully tumors,
defined by a predictive classifier, that become low risk when
treated with adjuvant chemotherapy or radiation.
Therefore, for this purpose, this prognostic classifier
should have been derived only using patients who received no
adjuvant therapy. The inclusion of patients who received
adjuvant therapy into the training set dooms the results to
failure in this regard. Specifically, individual patients at high
risk of relapse without adjuvant therapy, but who benefited
from adjuvant therapy and became low risk (did not relapse)
because of it, would be falsely forced into the low-risk group
of patients by this approach. Resulting classifiers would only
identify patients who do poorly and don’t do any better with
adjuvant therapy. The subset analysis presented in the article
showed that after definition of this classifier, high-risk patients
showed no benefit from adjuvant chemotherapy, which confirms
this problem. If the question is definition of mechanisms driving
relapse, active pathways in untreated patients who relapse
should be compared with untreated patients who don’t, and this
may define novel therapy targets that may alter this behavior.
The use of patients homogeneous for the relevant clin-
ical questions is thus absolutely essential. Many of the pa-
tients in this study had “unknown” adjuvant treatments.
Samples with incomplete clinical annotation should not be
included at all in any modern analysis, and treated patients
should not be lumped with untreated ones, if the intent is to
identify patients at risk for relapse and who might benefit
from these therapies. The era of definition of classifiers using
“samples of convenience” accumulated for the purpose of
large numbers and good p values should end.
Although difficult, accounting for the major genetic
subsets in expression array studies, defining the exact ques-
tion being asked, and using appropriate clinical cohorts
should be expected today. As our state of knowledge pro-
gresses, the general approach to defining broad categories of
tumors that behave more or less alike with only moderate
degrees of certainty will hopefully give way to a day when
tumors are characterized by possibly dozens of potently
predictive patterns of inherited differences, acquired muta-
tions, altered gene and protein expression, post-translational
modifications, and signaling patterns, with therapies designed
to match each pattern. We need to stop treating lung cancer as
a single disease at all levels of analysis and clearly define our
clinical goals when designing our research experiments.
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Response:
Dr. David Carbone makes several points on our man-
uscript which he feels are problematic and suggests clinical-
ly-actionable subsets by expression array technology, as de-
scribed in our paper are not successful because: 1) they are
typically tied to a particular way of looking at the cancer cell,
ignoring all others, and 2) they fail to carefully define the
clinical problem they are addressing and choose sample sets
and analyses appropriate to answer this question rather than
whatever is conveniently available. Although we do not agree
with his conclusions, we think they are interesting and im-
portant issues and we welcome the opportunity to discuss
them. As detailed in our manuscript by Chen et al, we
hypothesized that there are diverse survival-related processes
that are associated with lung adenocarcinomas and we then
actively attempted to incorporate this heterogeneity into a
model by using representation of small numbers of genes
from as many diverse survival-related clusters (presumably
cell processes) as possible. This is in contrast to many models
where the most significant survival-related genes are used
regardless of whether they are associated with the same
underlying biological process or not. Our goal was to develop
a model that was broadly useable for a diverse tumor popu-
lation such as that seen in lung adenocarcinomas and where
we as yet do not know all of the processes that are critical for
defining patient outcome. While we do not disagree with his
comments regarding ALK fusions or EGFR-mutant lung
adenocarcinomas, these tumors which are from non-smokers
are clearly genomically more stable, and quite unlike the vast
majority of lung cancers. In fact, Dr. Carbone admits that
there are a handful of genes that may significantly define
subsets; we humbly submit that these form a small slice of the
pie which are defined by complex alterations in multiple
pathways. Although it is tempting to hope that gene muta-
tions will clearly define other subgroups as Dr. Carbone
suggests, analyses done with our collaborators (Ding et al,
Nature, 2008) reveal that lung adenocarcinomas often have
very large numbers of simultaneous mutations, many occur-
ring at low frequency and unfortunately may not neatly divide
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these tumors into subgroups. The potential that single muta-
tions in these smoker-associated adenocarcinomas will define
dramatic responses to a therapy is unfortunately also much
less likely, although important to determine.
We certainly agree with Dr. Carbone that the survival
outcome might be impacted by a multitude of different
factors including inherited differences, acquired mutations,
altered gene and protein expression, post-translational mod-
ifications and signaling patterns. If such factors had been
available in the training set we would have included them in
the classifier. These were not available and at the current
time, are generally not going to be available on newly
diagnosed lung cancer patients for which the classifier is
designed. One of the main purposes of our paper was to
demonstrate that a classifier can bridge from one platform to
a different platform. This is an important issue and if these
other biological factors and processes are to be included in
the classifier they will have to be available in very transport-
able platforms.
The issue that we lump adenocarcinomas with squa-
mous tumors is also incorrect as gene selection and develop-
ment of the model was done only using adenocarcinomas as
our training set with the mixed tumors population only used
for validation assessments as independent test sets. That some
similar survival-related genes and cellular processes are pres-
ent in both adenocarcinomas and squamous tumors is not
unexpected as we have previously reported this observation
(Raponi et al, Cancer Research 2008).
We do agree that it is important to consider what is an
appropriate patient population to develop a prognostic classifier
and what patient populations does the classifier apply to. Dr.
Carbone suggests that the classifier should have only been
derived using patients who received no adjuvant therapy. Inclu-
sion of patients who received adjuvant therapy into the training
set he contends dooms the results to failure. Yet this does not
agree with our observations. First, the majority of our training
set is made up of stage I lung adenocarcinomas which only
received therapy when they have recurrent disease and most will
eventually receive some therapy. Second, while adjuvant ther-
apy was given to stage II and III patients after surgical resection
rarely does this result in dramatic survival benefit. In fact both
the IALT and the CALGB studies reveal a fading of benefit
beyond 7 years. JBR 10 which continued to demonstrate a
survival benefit consisted of a homogenous population able to
tolerate cisplatin and vinorelbine (not the adjuvant therapy of
choice for most patients in the US). Our retrospective cohorts
reflect patient populations when EGFR TKIs were less com-
monly used and adjuvant therapy primarily involved receiving
cisplatin-based treatment following surgery. The key question is
whether the genes associated with the outcome of higher stage
and lower stage patients are similar or different, and whether
adjuvant therapy in some patients indeed biased the genes
selected. We would argue that inclusion of higher stage patients
helps identify processes associated with aggressive disease and
these processes are similar to those occurring inthe high-risk
early stage I patients. The effect of adjuvant therapy is certainly
present, but given the low efficacy of therapy to significantly
affect patient survival a dramatic and major effect is less likely.
Further if this affect was so significant then the prognostic
classifier we (and others) have developed should not define
high-risk and low-risk stage I patients, but they do.
Dr. Carbone asks what is the clinical question of
interest? Our work is centrally motivated by the observation
that a significant number of stage I patients do not survive,
and if we could identify patients at high risk for early death,
that it may be beneficial to give such patients therapy in
addition to their surgery. These patients might be appropriate
to enroll in clinical trials using novel treatments. A related
use of a prognostic classifier is to identify those stage II
patients who are deemed very low risk and consider giving
such patients less aggressive therapy.
Dr. Carbone makes the distinction between prognostic
and predictive classifiers. In our paper we develop a prog-
nostic classifier. We share with Dr. Carbone the desire to
move to the next stage and develop predictive classifiers to
identify who is likely to benefit from other therapy. To find
such predictive classifiers, large datasets, preferably from
randomized trails, will be needed.
We acknowledge that while the classifier we developed
did demonstrate significance in test datasets, the strength of
the classification is not sufficiently large to expect to have a
large impact. Improvement in the classifier is certainly
needed and classifiers that incorporate other biological pro-
cesses are likely to improve the performance. Given that we
still do not know all the critical processes defining patient
prognosis in lung adenocarcinoma, or how to define patient
population subgroups our method is a reasonable approach
and our findings are encouraging that this avenue of research
will be clinically useful.
Guoan Chen, MD, PhD
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